Emerging Technology Partners
17
12M
15
0.71
4
0.12
8
- Stages of investment
- Areas of investment
Summary
Emerging Technology Partners is the famous VC, which was founded in 2000. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the San Francisco.
The fund was created by Wei-Wu He. Besides them, we counted 1 critical employee of this fund in our database.
The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 10 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Emerging Technology Partners performs on 31 percentage points more the average number of lead investments. The high activity for fund was in 2019. The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2015.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Emerging Technology Partners, startups are often financed by Solstice Capital, Village Ventures, Valley Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, MPM Capital, Alta Partners. In the next rounds fund is usually obtained by TPG, InterWest Partners, Alta Partners.
Among the most successful fund investment fields, there are Biotechnology, Genetics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight CASI Pharmaceuticals, Polaris Biology, Intradigm Corporation. The fund has exact preference in a number of founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 17
- Lead investments
- 4
- Exits
- 8
- Rounds per year
- 0.71
- Follow on index
- 0.12
- Investments by industry
- Biotechnology (14)
- Health Care (11)
- Medical (8)
- Genetics (6)
- Health Diagnostics (4) Show 8 more
- Investments by region
-
- United States (12)
- China (5)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
- Avg. valuation at time of investment
- 68M
- Group Appearance index
- 0.71
- Avg. company exit year
- 10
- Avg. multiplicator
- 0.60
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Heranova Lifesciences | 28 Dec 2023 | Biotechnology, Health Care, Medical | Seed | 3M | Shanghai, Huangpu, China |
| Intradigm Corporation | 21 Nov 2006 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 16M | United States, California, Palo Alto |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.